Image Credit: UKRI
CMAC are delighted to announce a new £5M award from EPSRC to establish and lead the new Made Smarter Innovation - Digital Medicines Manufacturing Research Centre (DM2). This award continues to build CMAC’s research portfolio and is part of the UKRI and Made Smarter Innovation £53 million investment in smart manufacturing and connected supply chain research and innovation.
DM2 is led by the University of Strathclyde (CMAC) in partnership with Loughborough and Cambridge Universities and is supported by a vibrant consortium of 28 project partners from across specialty pharma, digital software and hardware providers, robotics, simulation tools and pharmaceutical technology. The collaborating partners are contributing over £2.9M to co-create and co-deliver the research. The Centre’s goal is to accelerate the adoption of industry digital technologies (IDTs) across the pharma sector and transform data driven medicines development and manufacture. The Centre will address patient needs through establishing a foundational data platform, autonomous robotic oral medicine development and manufacturing system, a revolutionary digital quality control (QC) capability, investigate on demand patient-centric supply and develop and empower the digitally literate workforce of the future.
Prof Alastair Florence, PI of the DM2 Research Centre said: “This fantastic news allows us to address key challenges in the digitalisation of medicines development, manufacture and supply. We aim to unleash the potential impact of IDTs across the value chain to dramatically reduce waste, lead times and quality control costs, increase productivity and enhance the agility and efficiency of clinical trial supply chains, vital to the introduction of new therapies. Our impact focussed programme will benefit not only manufacturing industry and healthcare providers but also, ultimately, patients.”
“These ambitious targets demand a transformation in the way that data across pharma's supply chain are captured, stored, shared, processed, modelled and used. The integrated research test beds in DM2 will connect data, IDTs and drug product manufacturing processes to deliver this transformation.”
The Research Centre will also work with the community to drive the cultural change and skills development required to support IDT adoption. Prof Florence explained “The award will support the DM2 network to engage users in all stages of research, showcase the value of data and IDTs and encourage innovation. Working with stakeholders we will identify training needs to drive data literacy and enable the future, augmented workforce that trust data and IDTs and convert data into knowledge into action.”
The team working with the PI to deliver the DM2 Research Centre aims include the Industry Engagement Lead, Massimo Bresciani and Platform leads Prof Blair Johnston, Dr Daniel Markl and Dr Andrea Johnston (Strathclyde), Dr Brahim Benyahia (Loughborough) and Dr Jag Srai (Cambridge).
For more information and to find out how to engage with the programme, please contact Prof Alastair Florence: email@example.com.
Further information on the scheme:
The Made Smarter Innovation - Digital Medicines Manufacturing Research Centre is one of 5 University led research centres that will receive a share of £25 million to help the UK’s manufacturing industry become more productive and competitive through innovation and adoption of digital technologies. As well as being at the forefront and driving developments in their areas of expertise, these research centres will connect across the challenge to help bridge the gap between basic research and its application in manufacturing to provide a pipeline of digital technologies for the future.
February’s meeting, jointly run between MIT and CMAC Future Manufacturing Research Hub, brought together over 350 pharmaceutical industrialists, regulators, policy makers and academics from more than 22 countries and 142 organisations to inform strategies to grow medicines manufacturing in the UK and internationally, through accelerating the adoption of advanced manufacturing and digital technologies.
The UK already benefits from an excellent research base, investments in innovation centres, leading pharmaceutical manufacturers, dynamic technology and supply chain partners and a leading, independent national regulator, the MHRA. Given the strategic importance and opportunities for growth in the medicines manufacturing sector, a number of recommendations are made to strengthen the UK’s position as a leading location to develop, design, manufacture and supply medicines.
The full document and recommendations across industry, academia and regulatory can be viewed here.
This meeting was hosted by the joint MIT CMAC ISCMP Steering Team. Registration and attendance was at no charge to participants.
Continuous flow chemical reactor manufacturer Laminar Co Ltd (Jungwon-gu, Republic of Korea), represented in the UK and Ireland by Analytik Ltd (Cambridge, UK), have joined the CMAC Future Manufacturing Research Hub as tier 2 members from October 2020.
Laminar manufactures the world’s first commercially available chemical reactors which utilise Taylor Fluid Flow to synthesize high-purity, uniform substances. The patented design chemical reactors use a jacketed cylindrical vessel with a central, rotating agitation bar to produce Taylor Flow mixing along the length of the vessel resulting in 3-times faster mass flow transfer compared to tank type reactors.
The partnership will see the first Taylor Flow Reactor installed in the UK at CMAC’s Technology Innovation Centre (TIC) site in Glasgow, which will initially be studied to greater understand the mechanisms and potential of the technology, explore new syntheses and be benchmarked against existing processes. The CMAC Future Manufacturing Research Hub brings together a research team at Strathclyde, as well as other leading academic groups and an array of industry partners to address the urgent need to translate new molecules into high-value products through rapid predictive development pathways and integrated continuous manufacturing systems.
Analytik announced a partnership with Laminar to distribute their Taylor Flow Reactors in the UK and Ireland in 2019. Specialists in providing and supporting pioneering technology, it will oversee the installation of a Tera3100-HC Laminar Continuous Taylor Reactor (LCTR®) at CMAC in early 2021, as well as provide ongoing technical and service support over 3 years.
Speaking about the membership, Ian Laidlaw, Managing Director at Analytik said “We are delighted to be joining the CMAC Future Manufacturing Research Hub and excited to be facilitating the first LCTR® chemical reactor installation in the UK. This fantastic technology sets a new standard for high yield synthesis of high-purity, uniform substances and offers faster, more efficient continuous processing”.
Professor Alastair Florence, Director of CMAC added “It is a pleasure to welcome Laminar and Analytik to CMAC’s community. This partnership brings exciting new opportunities for our research team to work with this unique Taylor Flow Reactor platform to explore the potential for this advanced technology across reaction, work-up, purification and particle engineering for pharmaceutical systems. This technology will extend our Digital Twin and MicroFactory platforms for continuous manufacturing and create real benefits and impacts to our stakeholders though enabling faster process and product development and reducing the cost and environmental impact of medicines manufacture.”
You can find out more about Laminar Continuous Taylor Reactors (LCTR) by visiting the Analytik website: https://analytik.co.uk/product/continuous-flow-reactor/.
The LCTR®-Tera 3100 & 3300.
The CMAC Future Manufacturing Research Hub will address the urgent need to translate new molecules into high-value products through rapid predictive development pathways and integrated continuous manufacturing systems, enabling more personalised, responsive and flexible product provision through digitalised supply chains. Building on the significant success of the EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, and informed by extensive engagement with national and global industry, end-users, technology providers, international academic programmes and regulatory agencies, the industry-academic team has co-created an ambitious CMAC Future Manufacturing Research Hub Vision. www.cmac.ac.uk
For over 15 years Analytik has been a trusted supplier of cutting-edge scientific instrumentation to leading organisations throughout the UK and Ireland. Specialists in providing and supporting pioneering technology, it delivers added value through specialised consultative expertise and comprehensive pre- and post-sales support to ensure that customers get the most out of their investment. For further information please visit http://analytik.co.uk/.
Founded in 2010, South Korean-based Laminar has patented the world’s first commercially available Taylor Flow Reactor (LCTR®) and continues to develop manufacturing processes and expand its product range, which can be applied to various fields, such as secondary batteries, pharmaceuticals, graphene oxide, food additives and nanomaterials.
Karina Davies, Analytik – firstname.lastname@example.org
Stewart Mitchell, CMAC – email@example.com
CMAC and PwC are delighted to share ‘The Business Case Insights for Continuous Manufacturing’. This joint document, with input from industrial partners, seeks to review key considerations for building a successful business case for the industrial adoption of innovative Continuous Manufacturing (CM) technologies.
The report is written from the perspective of the CMAC manufacturing research programme stakeholders. Hence, it targets factors directly relevant to continuous small molecule pharmaceutical manufacture and although addresses the many drivers and impacts across the entire value chain, brings a strong emphasis on factors relevant to continuous drug substance manufacture.
With the associated growth in new technologies and services comes the opportunity for different business models that exploit CM to deliver additional value and tackle major challenges facing the sector: how are we to manage spiralling prescription medicine costs in the NHS and other global healthcare systems; can the pharmaceutical supply chain deliver greater personalisation of medicines quickly and cost effectively; can the security of global medicines supply be assured to maintain access to essential medicines or respond to medical emergencies; how can the impact of medicines manufacture on the environment be minimised and made more sustainable? Those that can best harness the potential of innovative technologies such as CM will be best placed to meet these challenges.
Nine critical considerations have been highlighted for business case development. Through each of these lenses, a holistic case for continuous manufacturing can be progressed to help drive the uptake of this currently novel technology.
Please view full document here
This document was undertaken with engagement from CMAC Tier 1 partners AstraZeneca, Eli Lilly, Pfizer and Takeda as well as leveraging CMAC’s own extensive academic portfolio on end-to-end (E2E) processing. CMAC would like to thank all those who have contributed information and viewpoints on key technical aspects in combination with PwC’s wider business case perspective, to help inform and engage senior stakeholders and drive continuous manufacturing forward.
CMAC is #hiring! 📢
Do you want to make a difference in the world of #medicinesmanufacturing research? We have some amazing opportunities to join #CMAC, a world leading research centre at the heart of cutting edge innovation.
💊 We are always looking for diverse and inspiring talent
💊 We offer flexible and agile working across our opportunities
💊 We have roles for various skills and career stages
With over 10 vacancies available and more in the pipeline, there has never been a better time to contribute to our broad portfolio of #research, #translation and #skills in award-winning #facilities in #collaboration with global #pharma and technology providers.
Funding Announcement: Made Smarter Innovation Digital Medicines Manufacturing Research Centre
Funding Announcement: Made Smarter Innovation - Digital Medicines Manufacturing Research Centre
CMAC are delighted to announce a new £5M award from EPSRC to establish and lead the new Made Smarter Innovation - Digital Medicines Manufacturing Research Centre (DM2). This award continues to build CMAC’s research portfolio and is part of the UKRI and Made Smarter Innovation £53 million investment in smart manufacturing and connected supply chain research and innovation. .... more